Nanocarriers: A general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs

Current Drug Metabolism

Volumn 11, Issue 2, 2010, Pages 197-207

  Cai, Zheng ^a   Wang, Yan ^b,c   Zhu, Li Jun ^a   Liu, Zhong Qiu ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

Author keywords

Bioavailability; Drug carrier; Gastrointestinal absorption; Nanoparticle; Oral delivery; Pharmacokinetics; Pre systemic metabolism

Indexed keywords

BETA LACTAMASE; CHITOSAN; CURCUMIN; CYCLOSPORIN A; DENDRIMER; DRUG CARRIER; NANOCARRIER; NANOPARTICLE; OLEANOLIC ACID; PACLITAXEL; PENETRATION ENHANCING AGENT; PRIMAQUINE; RAMIPRIL; TACROLIMUS; THYMOPENTIN;

BIOCOMPATIBILITY; CELL TRANSPORT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; GASTROINTESTINAL ABSORPTION; HUMAN; INTESTINE CELL; INTESTINE EPITHELIUM; INTESTINE FLUID; INTESTINE MUCOSA; MOLECULE; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; REVIEW; ROTAVIRUS; SURFACE PROPERTY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; HUMANS; INTESTINAL ABSORPTION; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 77950791815     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010791110836     Document Type: Review

References (110)

1. Sakuma, S.; Hayashi, M.; Akashi, M. Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv. Drug Deliv. Rev., 2001, 47(1), 21-37.
2. Singh, R.; Lillard, J.W., Jr. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol., 2009, 86(3), 215-223.
3. Ramesan, R.M.; Sharma, C.P. Challenges and advances in nanoparticle-based oral insulin delivery. Expert Rev. Med. Devices, 2009, 6(6), 665-676.
4. Lalanne, M.; Andrieux, K.; Couvreur, P. Strategies to increase the oral bioavailability of nucleoside analogs. Curr. Med. Chem., 2009, 16(11), 1391-1399.
5. Merisko-Liversidge, E.M.; Liversidge, G.G. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol., 2008, 36(1), 43-48.
6. Singh, R.; Singh, S.; Lillard, J.W., Jr. Past, present, and future technologies for oral delivery of therapeutic proteins. J. Pharm. Sci., 2008, 97(7), 2497-2523.
7. des Rieux, A.; Fievez, V.; Garinot, M.; Schneider, Y.J.; Preat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control Release, 2006, 116(1), 1-27.
8. Hwang, S.J.; Park, H.; Park, K. Gastric retentive drug-delivery systems. Crit. Rev. Ther. Drug Carrier Syst., 1998, 15(3), 243-284.
9. Petrovic, V.; Teng, S.; Piquette-Miller, M. Regulation of drug transporters during infection and inflammation. Mol. Interv., 2007, 7(2), 99-111.
10. Liu, Z.; Hu, M. Natural polyphenol disposition via coupled metabolic pathways. Expert Opin. Drug Metab. Toxicol., 2007, 3(3), 389-406.
11. Burton, A.; Monasch, R.; Lautenbach, B.; Gacic-Dobo, M.; Neill, M.; Karimov, R.; Wolfson, L.; Jones, G.; Birmingham, M. WHO and UNICEF estimates of national infant immunization coverage: methods and processes. Bull World Health Organ., 2009, 87(7), 535-541.
12. Jeong, E.J.; Liu, X.; Jia, X.; Chen, J.; Hu, M. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr. Drug Metab., 2005, 6(5), 455-468.
13. Hu, M.; Cheng, Z.; Zheng, L. Functional and molecular characterization of rat intestinal prolidase. Pediatr. Res., 2003, 53(6), 905-914.
14. Bock, K.W.; Bock-Hennig, B.S. UDP-glucuronosyltransferases (UGTs): from purification of Ah-receptor-inducible UGT1A6 to coordinate regulation of subsets of CYPs, UGTs, and ABC transporters by nuclear receptors. Drug Metab. Rev., 42(1), 5-12.
15. Xu, H.; Kulkarni, K.H.; Singh, R.; Yang, Z.; Wang, S.W.; Tam, V.H.; Hu, M. Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol. Pharm., 2009, 6(6), 1703-1715.
16. Hu, M.; Chen, J.; Lin, H. Metabolism of flavonoids via enteric recycling: mechanistic studies of disposition of apigenin in the Caco-2 cell culture model. J. Pharmacol. Exp. Ther., 2003, 307(1), 314-321.
17. Woitiski, C.B.; Carvalho, R.A.; Ribeiro, A.J.; Neufeld, R.J.; Veiga, F. Strategies toward the improved oral delivery of insulin nanoparticles via gastrointestinal uptake and translocation. BioDrugs, 2008, 22(4), 223-237.
18. Blanchette, J.; Kavimandan, N.; Peppas, N.A. Principles of transmucosal delivery of therapeutic agents. Biomed. Pharmacother., 2004, 58(3), 142-151.
19. Shakweh, M.; Ponchel, G.; Fattal, E. Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery. Expert Opin. Drug Deliv., 2004, 1(1), 141-163.
20. Salama, N.N.; Eddington, N.D.; Fasano, A. Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev., 2006, 58(1), 15-28.
21. Camenisch, G.; Alsenz, J.; van de Waterbeemd, H.; Folkers, G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur. J. Pharm. Sci., 1998, 6(4), 317-324.
22. Swaan, P.W. Recent advances in intestinal macromolecular drug delivery via receptor-mediated transport pathways. Pharm Res., 1998, 15(6), 826-834.
23. Sigfridsson, K.; Lundqvist, A.J.; Strimfors, M. Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development. Drug Dev. Ind. Pharm., 2009, 35(12), 1479-1486.
24. Kadiyala, I.; Loo, Y.; Roy, K.; Rice, J.; Leong, K.W. Transport of chitosan-DNA nanoparticles in human intestinal M-cell model versus normal intestinal enterocytes. Eur. J. Pharm. Sci., 2009.
25. Paliwal, R.; Rai, S.; Vaidya, B.; Khatri, K.; Goyal, A.K.; Mishra, N.; Mehta, A.; Vyas, S.P. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine, 2009, 5(2), 184-191.
26. Trevaskis, N.L.; Charman, W.N.; Porter, C.J. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv. Drug Deliv. Rev., 2008, 60(6), 702-716.
27. Kesisoglou, F.; Panmai, S.; Wu, Y. Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev., 2007, 59(7), 631-644.
28. Florence, A.T.; Hillery, A.M.; Hussain, N.; Jani, P.U. Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J. Drug Target, 1995, 3(1), 65-70.
29. Desai, M.P.; Labhasetwar, V.; Walter, E.; Levy, R.J.; Amidon, G.L. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res., 1997, 14(11), 1568-1573.
30. Desai, M.P.; Labhasetwar, V.; Amidon, G.L.; Levy, R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res., 1996, 13(12), 1838-1845.
31. Mauludin, R.; Muller, R.H.; Keck, C.M. Development of an oral rutin nanocrystal formulation. Int. J. Pharm., 2009, 370(1-2), 202-209.
32. Pandita, D.; Ahuja, A.; Velpandian, T.; Lather, V.; Dutta, T.; Khar, R.K. Characterization and in vitro assessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique. Pharmazie, 2009, 64(5), 301-310.
33. Jani, P.; Halbert, G.W.; Langridge, J.; Florence, A.T. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol., 1990, 42(12), 821-826.
34. Yellepeddi, V.K.; Kumar, A.; Palakurthi, S. Surface modified poly(amido)amine dendrimers as diverse nanomolecules for biomedical applications. Expert Opin. Drug Deliv., 2009, 6(8), 835-850.
35. Jepson, M.A.; Simmons, N.L.; O'Hagan, D.T.; Hirst, B.H. Comparison of poly(DL-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells. J. Drug Target, 1993, 1(3), 245-249.
36. Norris, S.; Crosbie, O.; McEntee, G.; Traynor, O.; Nolan, N.; McCann, S.; Hegarty, J. Orthotopic liver transplantation for veno-occlusive disease complicating autologous bone marrow transplantation. Transplantation, 1997, 63(10), 1521-1524.
37. McDowell, A.; McLeod, B.J.; Rades, T.; Tucker, I.G. Polymeric nanoparticles as an oral delivery system for biocontrol agents for the brushtail possum ( Trichosurus vulpecula ). N Z Vet J, 2009, 57(6), 370-377.
38. Cui, F.; Qian, F.; Zhao, Z.; Yin, L.; Tang, C.; Yin, C. Preparation, characterization, and oral delivery of insulin loaded carboxylated chitosan grafted poly(methyl methacrylate) nanoparticles. Biomacromolecules, 2009, 10(5), 1253-1258.
39. Jani, P.; Halbert, G.W.; Langridge, J.; Florence, A.T. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J. Pharm. Pharmacol., 1989, 41(12), 809-812.
40. Mathiowitz, E.; Jacob, J.S.; Jong, Y.S.; Carino, G.P.; Chickering, D.E.; Chaturvedi, P.; Santos, C.A.; Vijayaraghavan, K.; Montgomery, S.; Bassett, M.; Morrell, C. Biologically erodable microspheres as potential oral drug delivery systems. Nature, 1997, 386(6623), 410-414.
41. Yin, L.; Ding, J.; He, C.; Cui, L.; Tang, C.; Yin, C. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials, 2009, 30(29), 5691-5700.
42. Salman, H.H.; Gamazo, C.; Campanero, M.A.; Irache, J.M. Bioadhesive mannosylated nanoparticles for oral drug delivery. J. Nano-sci. Nanotechnol., 2006, 6(9-10), 3203-3209.
43. Petrus, A.K.; Fairchild, T.J.; Doyle, R.P. Traveling the vitamin B12 pathway: oral delivery of protein and peptide drugs. Angew. Chem. Int. Ed. Engl., 2009, 48(6), 1022-1028.
44. Ponchel, G.; Irache, J. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev., 1998, 34(2-3), 191-219.
45. Vyas, S.P.; Gupta, P.N. Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev. Vaccines, 2007, 6(3), 401-418.
46. Misumi, S.; Masuyama, M.; Takamune, N.; Nakayama, D.; Mitsumata, R.; Matsumoto, H.; Urata, N.; Takahashi, Y.; Muneoka, A.; Sukamoto, T.; Fukuzaki, K.; Shoji, S. Targeted delivery of immunogen to primate m cells with tetragalloyl lysine dendrimer. J. Immunol., 2009, 182(10), 6061-6070.
47. Florence, A.T.; Sakthivel, T.; Toth, I. Oral uptake and translocation of a polylysine dendrimer with a lipid surface. J. Control Release, 2000, 65(1-2), 253-259.
48. Zhang, N.; Ping, Q.; Huang, G.; Han, X.; Cheng, Y.; Xu, W. Transport characteristics of wheat germ agglutinin-modified insulin-liposomes and solid lipid nanoparticles in a perfused rat intestinal model. J. Nanosci. Nanotechnol., 2006, 6(9-10), 2959-2966.
49. Ross, B.P.; Toth, I. Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers. Curr. Drug Deliv., 2005, 2(3), 277-287.
50. Samstein, R.M.; Perica, K.; Balderrama, F.; Look, M.; Fahmy, T.M. The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles. Biomaterials, 2008, 29(6), 703-708.
51. Varshosaz, J.; Minayian, M.; Moazen, E. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J. Liposome Res., 2009, [Epub ahead of Print].
52. Yuan, H.; Jiang, S.P.; Du, Y.Z.; Miao, J.; Zhang, X.G.; Hu, F.Q. Strategic approaches for improving entrapment of hydrophilic peptide drugs by lipid nanoparticles. Colloids Surf. B Biointerfaces, 2009, 70(2), 248-253.
53. Varshosaz, J.; Tabbakhian, M.; Mohammadi, M.Y. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J. Liposome Res., 2009.
54. Sawant, K.K.; Dodiya, S.S. Recent advances and patents on solid lipid nanoparticles. Recent Pat. Drug Deliv. Formul., 2008, 2(2), 120-135.
55. Li, H.; Zhao, X.; Ma, Y.; Zhai, G.; Li, L.; Lou, H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J. Control Release, 2009, 133(3), 238-244.
56. Almeida, A.J.; Souto, E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev., 2007, 59(6), 478-490. (Pubitemid 47260710)
57. Shidhaye, S.S.; Vaidya, R.; Sutar, S.; Patwardhan, A.; Kadam, V.J. Solid lipid nanoparticles and nanostructured lipid carriers - innovative generations of solid lipid carriers. Curr. Drug Deliv., 2008, 5(4), 324-331.
58. Muchow, M.; Maincent, P.; Muller, R.H. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev. Ind. Pharm., 2008, 34(12), 1394-1405.
59. Date, A.A.; Joshi, M.D.; Patravale, V.B. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev., 2007, 59(6), 505-521.
60. Zhang, Z.; Lv, H.; Zhou, J. Novel solid lipid nanoparticles as carriers for oral administration of insulin. Pharmazie, 2009, 64(9), 574-578.
61. Yang, L.; Geng, Y.; Li, H.; Zhang, Y.; You, J.; Chang, Y. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmazie, 2009, 64(2), 86-89.
62. Sanjula, B.; Shah, F.M.; Javed, A.; Alka, A. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J. Drug Target, 2009, 17(3), 249-256.
63. Martins, S.; Sarmento, B.; Ferreira, D.C.; Souto, E.B. Lipid-based colloidal carriers for peptide and protein delivery - liposomes versus lipid nanoparticles. Int. J. Nanomed., 2007, 2(4), 595-607.
64. Zhang, N.; Ping, Q.; Huang, G.; Xu, W.; Cheng, Y.; Han, X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm., 2006, 327(1-2), 153-159. (Pubitemid 44667334)
65. Singh, K.K.; Vingkar, S.K. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int. J. Pharm., 2008, 347(1-2), 136-143.
66. Nazzal, S.; Smalyukh, II; Lavrentovich, O.D.; Khan, M.A. Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: mechanism and progress of emulsion formation. Int. J. Pharm., 2002, 235(1-2), 247-265.
67. Constantinides, P.P. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res., 1995, 12(11), 1561-1572.
68. Shafiq, S.; Shakeel, F.; Talegaonkar, S.; Ahmad, F.J.; Khar, R.K.; Ali, M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur. J. Pharm. Biopharm., 2007, 66(2), 227-243.
69. Lawrence, M.J.; Rees, G.D. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev., 2000, 45(1), 89-121.
70. Ke, W.T.; Lin, S.Y.; Ho, H.O.; Sheu, M.T. Physical characterizations of microemulsion systems using tocopheryl polyethylene glycol 1000 succinate (TPGS) as a surfactant for the oral delivery of protein drugs. J. Control Release, 2005, 102(2), 489-507.
71. Kawakami, K.; Yoshikawa, T.; Hayashi, T.; Nishihara, Y.; Masuda, K. Microemulsion formulation for enhanced absorption of poorly soluble drugs. II. In vivo study. J. Control Release, 2002, 81(1-2), 75-82. (Pubitemid 34454851)
72. Khandavilli, S.; Panchagnula, R. Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. J. Invest. Dermatol., 2007, 127(1), 154-162. (Pubitemid 46005673)
73. Xi, J.; Chang, Q.; Chan, C.K.; Meng, Z.Y.; Wang, G.N.; Sun, J.B.; Wang, Y.T.; Tong, H.H.; Zheng, Y. Formulation development and bioavailability evaluation of a self-nanoemulsified drug delivery system of oleanolic acid. AAPS Pharm. Sci.Tech., 2009, 10(1), 172-182.
74. Rao, S.V.; Shao, J. Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs: I. Formulation development. Int. J. Pharm., 2008, 362(1-2), 2-9.
75. Rao, S.V.; Agarwal, P.; Shao, J. Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs: II. In vitro transport study. Int. J. Pharm., 2008, 362(1-2), 10-15.
76. Rao, S.V.; Yajurvedi, K.; Shao, J. Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of protein drugs: III. In vivo oral absorption study. Int. J. Pharm., 2008, 362(1-2), 16-19.
77. Werle, M.; Takeuchi, H.; Bernkop-Schnurch, A. Modified chitosans for oral drug delivery. J. Pharm. Sci., 2009, 98(5), 1643-1656.
78. Bowman, K.; Leong, K.W. Chitosan nanoparticles for oral drug and gene delivery. Int. J. Nanomed., 2006, 1(2), 117-128.
79. Rekha, M.R.; Sharma, C.P. Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption. J. Control Release, 2009, 135(2), 144-151.
80. Atyabi, F.; Talaie, F.; Dinarvand, R. Thiolated chitosan nanoparticles as an oral delivery system for Amikacin: in vitro and ex vivo evaluations. J. Nanosci. Nanotechnol., 2009, 9(8), 4593-4603.
81. Prego, C.; Torres, D.; Fernandez-Megia, E.; Novoa-Carballal, R.; Quinoa, E.; Alonso, M.J. Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. J. Control Release, 2006, 111(3), 299-308.
82. Sarmento, B.; Ribeiro, A.; Veiga, F.; Sampaio, P.; Neufeld, R.; Ferreira, D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm. Res., 2007, 24(12), 2198-2206. (Pubitemid 350060707)
83. Sarmento, B.; Ribeiro, A.; Veiga, F.; Ferreira, D.; Neufeld, R. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules, 2007, 8(10), 3054-3060. (Pubitemid 350011625)
84. Pan, Y.; Li, Y.J.; Zhao, H.Y.; Zheng, J.M.; Xu, H.; Wei, G.; Hao, J.S.; Cui, F.D. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int. J. Pharm., 2002, 249(1-2), 139-147.
85. Chen, J.; Yang, W.L.; Li, G.; Qian, J.; Xue, J.L.; Fu, S.K.; Lu, D.R. Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles. World J. Gastroenterol., 2004, 10(1), 112-116.
86. Bowman, K.; Sarkar, R.; Raut, S.; Leong, K.W. Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles. J. Control Release, 2008, 132(3), 252-259.
87. Li, F.; Wang, L.; Jin, X.M.; Yan, C.H.; Jiang, S.; Shen, X.M. The immunologic effect of TGF-beta1 chitosan nanoparticle plasmids on ovalbumin-induced allergic BALB/c mice. Immunobiology, 2009, 214(2), 87-99.
88. Borges, O.; Tavares, J.; de Sousa, A.; Borchard, G.; Junginger, H.E.; Cordeiro-da-Silva, A. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur. J. Pharm. Sci., 2007, 32(4-5), 278-290. (Pubitemid 350051890)
89. Duncan, R.; Izzo, L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev., 2005, 57(15), 2215-2237.
90. Najlah, M.; Freeman, S.; Attwood, D.; D'Emanuele, A. In vitro evaluation of dendrimer prodrugs for oral drug delivery. Int. J. Pharm., 2007, 336(1), 183-190. (Pubitemid 46551566)
91. Jevprasesphant, R.; Penny, J.; Attwood, D.; McKeown, N.B.; D'Emanuele, A. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm. Res., 2003, 20(10), 1543-1550. (Pubitemid 37268266)
92. Pisal, D.S.; Yellepeddi, V.K.; Kumar, A.; Kaushik, R.S.; Hildreth, M.B.; Guan, X.; Palakurthi, S. Permeability of surface-modified polyamidoamine (PAMAM) dendrimers across Caco-2 cell monolayers. Int. J. Pharm., 2008, 350(1-2), 113-121.
93. El-Sayed, M.; Ginski, M.; Rhodes, C.; Ghandehari, H. Transepithelial transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers. J. Control Release, 2002, 81(3), 355-365. (Pubitemid 34607155)
94. Kolhatkar, R.B.; Kitchens, K.M.; Swaan, P.W.; Ghandehari, H. Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug. Chem., 2007, 18(6), 2054-2060. (Pubitemid 350220008)
95. Kitchens, K.M.; Kolhatkar, R.B.; Swaan, P.W.; Eddington, N.D.; Ghandehari, H. Transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers: Influence of size, charge and fluorescent labeling. Pharm. Res., 2006, 23(12), 2818-2826. (Pubitemid 44885368)
96. Cheng, Y.; Xu, Z.; Ma, M.; Xu, T. Dendrimers as drug carriers: applications in different routes of drug administration. J. Pharm. Sci., 2008, 97(1), 123-143.
97. Pisal, D.S.; Yellepeddi, V.K.; Kumar, A.; Palakurthi, S. Transport of surface engineered polyamidoamine (PAMAM) dendrimers across IPEC-J2 cell monolayers. Drug Deliv., 2008, 15(8), 515-522.
98. Sweet, D.M.; Kolhatkar, R.B.; Ray, A.; Swaan, P.; Ghandehari, H. Transepithelial transport of PEGylated anionic poly(amidoamine) dendrimers: implications for oral drug delivery. J. Control Release, 2009, 138(1), 78-85.
99. Najlah, M.; Freeman, S.; Attwood, D.; D'Emanuele, A. Synthesis, characterization and stability of dendrimer prodrugs. Int. J. Pharm., 2006, 308(1-2), 175-182.
100. D'Emanuele, A.; Jevprasesphant, R.; Penny, J.; Attwood, D. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J. Control Release, 2004, 95(3), 447-453. (Pubitemid 38340495)
101. Tripathi, P.K.; Khopade, A.J.; Nagaich, S.; Shrivastava, S.; Jain, S.; Jain, N.K. Dendrimer grafts for delivery of 5-fluorouracil. Pharmazie, 2002, 57(4), 261-264.
102. Tokarska-Schlattner, M.; Wallimann, T.; Schlattner, U. Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. C. R. Biol., 2006, 329(9), 657-668. (Pubitemid 44283720)
103. Troutman, M.D.; Thakker, D.R. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm. Res., 2003, 20(8), 1210-1224.
104. Ke, W.; Zhao, Y.; Huang, R.; Jiang, C.; Pei, Y. Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J. Pharm. Sci., 2008, 97(6), 2208-2216.
105. Yang, Z.Q.; Xu, J.; Pan, P.; Zhang, X.N. Preparation of an alternative freeze-dried pH-sensitive cyclosporine A loaded nanoparticles formulation and its pharmacokinetic profile in rats. Pharmazie, 2009, 64(1), 26-31.
106. Shaikh, J.; Ankola, D.D.; Beniwal, V.; Singh, D.; Kumar, M.N. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci., 2009, 37(3-4), 223-230.
107. Nayak, B.; Panda, A.K.; Ray, P.; Ray, A.R. Formulation, characterization and evaluation of rotavirus encapsulated PLA and PLGA particles for oral vaccination. J. Microencapsul, 2009, 26(2), 154-165.
108. Nassar, T.; Rom, A.; Nyska, A.; Benita, S. Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. J. Control Release, 2009, 133(1), 77-84.
109. He, W.; Jiang, X.; Zhang, Z.R. Preparation and evaluation of polybutylcyanoacrylate nanoparticles for oral delivery of thymopentin. J. Pharm. Sci., 2008, 97(6), 2250-2259.
110. Yin, Y.; Chen, D.; Qiao, M.; Wei, X.; Hu, H. Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. J. Control Release, 2007, 123(1), 27-38. (Pubitemid 47444385)